Women's-health guide
Compounded vs Brand-Name GLP-1 for Women
What the compounded-vs-brand choice really means for women: what the evidence covers, what compounding is, and how to decide with a clinician.
On this page
Our pick for women
Grade ACoreAge Rx
93/100The most reliable on-ramp for women: nationwide access to both molecules at one flat, no-surprise price — including tirzepatide, the option many women with insulin resistance want.
Check availability- Semaglutide
- $99/mo
- Tirzepatide
- $149/mo
Also worth a look
HumeCare+
Grade CThe only desk here that titrates against lean mass rather than scale weight — a weekly body scan is included — and the only one that will not tell you a price before you finish its assessment.
Visit HumeCare+What each option actually is
Brand-name GLP-1 medicines — semaglutide sold as Wegovy, tirzepatide sold as Zepbound — are the exact products studied in the large clinical trials and reviewed by the FDA3. Compounded versions are made by pharmacies that prepare a medication to order. The FDA does not review or approve compounded drugs the way it does brand-name ones, and it has publicly flagged quality and dosing concerns with some compounded GLP-1 products45. That difference in oversight is the heart of the choice, and it is why this decision is worth making with a clinician rather than on price alone. This guide is educational only and not medical advice.
What the evidence does and does not cover
The efficacy numbers women see quoted come from brand-name products: about 15% mean weight loss with once-weekly semaglutide in STEP 11 and around 20% with tirzepatide in SURMOUNT-12. Those trials studied specific molecules at specific doses under monitoring. Compounded preparations are not the same as the trial product, so the published results do not automatically transfer to them. This matters for women who are making a real health decision on the strength of those numbers — the data belongs to the approved products.
Why the women's-health lens changes the weighting
For a woman with PCOS, in perimenopause, or relying on the pill, the value of a program is not only the drug in the vial — it is the oversight around it: labs, titration support, and someone who understands how a GLP-1 interacts with your hormones and contraception. Compounding can lower cost, and for some women cost is the deciding barrier to any treatment at all. But the trade-off is real, and a program that leans on compounding should still provide genuine clinical oversight, transparent sourcing, and a licensed prescriber — the factors our Luna Fit Score methodology rewards.
Transparent sourcing has a simple test: will the seller tell you which pharmacy compounds your vial. Most will not. Of seven sellers we read editorially in August 2026, one names its compounding pharmacy and its medical director's NPI, both of which we checked, while another refers only to "our pharmacy partner" and claims twenty states without listing one of them. Neither is in our ranking and neither pays us anything; the contrast is the point. If you cannot find out who made the medicine, you cannot ask any of the questions in this guide about how it was made.
How to decide
Ask which specific product you would receive and from what kind of pharmacy; whether a licensed clinician oversees dosing and follow-up; and what the total monthly cost is either way. If a program cannot answer plainly, that is an answer. Our guide to what a GLP-1 actually costs and how to start one safely explains the 503A and 503B pharmacy distinctions in more depth, and our provider-choice checklist walks through the rest of the conversation. If PCOS is what brought you here, our PCOS-specific ranking shows both molecule prices side by side for the programs that score highest on hormonal suitability. Whichever route you choose, choose it with a clinician who can see your whole picture.
Frequently asked questions
Do trial results apply to compounded GLP-1?
The published weight-loss figures come from brand-name products studied under monitoring. Compounded preparations are not the same as the trial product, so those results do not automatically transfer. Discuss the difference with a clinician.
Is compounded GLP-1 safe for women?
Compounded drugs are not FDA-reviewed the way brand-name ones are, and the FDA has flagged quality and dosing concerns with some products. If you consider a compounded route, insist on a licensed prescriber, transparent sourcing and real oversight.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
- U.S. Food and Drug Administration (2023). Wegovy (semaglutide) injection — prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration (2024). Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Keep exploring
Semaglutide vs Tirzepatide for Women: Insulin Resistance and Results
How semaglutide and tirzepatide compare for women — mechanism, weight-loss results and why insulin resistance shapes the choice.
Read the guide →What GLP-1 Costs and How to Start Safely
A measured women's-lens look at GLP-1 cost and starting safely: 503A vs 503B pharmacies, LegitScript, FDA compounding and what to verify.
Read the guide →GLP-1 and Muscle Loss in Women: What Midlife Changes
Some lean mass goes with any weight loss. Why midlife stacks that on a decline already underway — and what the evidence in women actually supports.
Read the guide →GLP-1 Medication and Bone Density: What Women Should Know
A GLP-1 trial in adults with fracture risk found lower hip and spine bone density at 52 weeks. What that means layered onto menopausal bone loss.
Read the guide →GLP-1 Medication and Breastfeeding: What the Evidence Actually Shows
The FDA label treats the semaglutide tablet and injection differently for breastfeeding. What the new human milk data shows, and what it doesn't yet.
Read the guide →GLP-1 Medication and Breast Cancer: History, Risk, and the Evidence
Obesity is a real, established risk factor for postmenopausal breast cancer. What new survivor data on GLP-1 use shows — and what questions remain open.
Read the guide →